Fig. 7
a In vivo real-time self-monitoring of drug distribution by observing fluorescence changes of ILA@Lip (AQ4N: 5 mg kg−1, Lenvatinib: 100 mg kg−1, IR 780: 5 mg kg−1) in subcutaneous 4T1 breast tumor-bearing mouse model. b In vivo real-time self-monitoring of drug distribution by observing fluorescence changes of ILA@Lip (AQ4N: 5 mg kg−1, Lenvatinib: 100 mg kg−1, IR 780: 5 mg kg−1) in orthotopic 4T1 breast tumor-bearing mouse model. c Fluorescence distribution of ILA@Lip in tumor and key organs from subcutaneous 4T1 breast tumor-bearing mouse model after 48 h post-injection. d Fluorescence distribution of ILA@Lip in tumor and key organs from and orthotopic 4T1 breast tumor-bearing mouse model after 48 h post-injection. e Statistical assay of the fluorescence intensity of the tumor region at 0, 3, 6, 12, 24, and 48 h after injection. Values represent means ± SD, n = 3. f Measurements of the fluorescence intensity of tumor and key organs. Values represent means ± SD, n = 3. g In vivo fluorescence images of 4T1 tumor metastasized to a lymph node. The images were acquired after tail vein injection of IAL@Lip for 6 h